Unknown

Dataset Information

Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.


ABSTRACT: Prostate cancer is the most common noncutaneous cancer and the second leading cause of death from cancer in men in most western countries. Advanced prostate cancer is typically sensitive to androgen-deprivation therapy, but invariably progresses to the castration-resistant state. Most current prostate cancer treatments are based on cytotoxicity directed against tumor cells via androgen-deprivation therapy or chemotherapy. Chemotherapy with docetaxel represents the standard first-line treatment in patients with castration-resistant prostate cancer (CRPC). Following progression after treatment with docetaxel, cabazitaxel (XRP6258)-prednisone treatment leads to a significantly longer overall survival (OS) time than with mitoxantrone-prednisone. Several other novel agents are currently being e

SUBMITTER: Sartor O 

PROVIDER: S-EPMC3233282 | biostudies-literature | 2011

REPOSITORIES: biostudies-literature